Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 47, 2013, Pages 8861-8866

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

Hepatitis b virus; Hepatocellular carcinoma; Interferon; Nucleotide analogues; Recurrence

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA FETOPROTEIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HYALURONIC ACID; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; VIRUS DNA;

ARTICLE; CANCER CONTROL; CANCER PROGNOSIS; CARCINOGENESIS; FOLLOW UP; GENE EXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; VIRUS LOAD;

HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; INTERFERON; NUCLEOTIDE ANALOGUES; RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DNA, VIRAL; HEPATECTOMY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84890902932     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i47.8861     Document Type: Article

References (44)

1. Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004; 127: S248-S260[PMID: 15508091 DOI: 10.1053/j.gastro.2004.09.039]
2. Ioannou GN, Perkins JD, Carithers RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterol-ogy 2008; 134: 1342-1351[PMID: 18471511 DOI: 10.1053/ j.gastro.2008.02.013]
3. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000; 217: 119-126[PMID: 11012432]
4. Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, Zangrandi A, Andreola S, Silverman D, Buscarini L. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol 1998; 170: 1015-1022[PMID: 9530052 DOI: 10.2214/ajr.170.4.9530052]
5. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, Paties CT, Silverman DE, Buscarini L. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996; 167: 759-768[PMID: 8751696 DOI: 10.2214/ajr.167.3.8751696]
6. Toyama T, Hiramatsu N, Yakushijin T, Oze T, Nakanishi F, Yasumaru M, Mochizuki K, Kanto T, Takehara T, Kasahara A, Hayashi N. A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution. J Clin Gastroenterol 2008; 42: 317-322[PMID: 18223490 DOI: 10.1097/MCG.0b013e3180ebe790]
7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200[PMID: 15918147 DOI: 10.1055/ s-2005-871198]
8. Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011; 11: 601-611[PMID: 22140383 DOI: 10.5812/kowsar.1735143X.451]
9. Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18: 1094-1101[PMID: 10694562]
10. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Inter-feron beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232[PMID: 10915728]
11. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967[PMID: 11352697 DOI: 10.7326/0003-4819-134-10-200105150-00010]
12. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, Kishimoto Y, Kohno M, Hirooka Y, Kawasaki H. Interferon alpha inhibits intrahepatic recurrence in hepato-cellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20: 301-311[PMID: 11404190 DOI: 10.1016/ S1386-6346(00)00148-0]
13. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocel-lular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306[PMID: 12585827 DOI: 10.7326/0003-4819-138-4-200302180-00008]
14. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 64-70[PMID: 15785092 DOI: 10.1159/000082097]
15. Ishikawa T. Secondary prevention of recurrence by interfer-on therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008; 14: 6140-6144[PMID: 18985803 DOI: 10.3748/wjg.14.6140]
16. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in trans-genic mice. Nature 1991; 351: 317-320PMID: 2034275 DOI: 10.1038/351317a0]
17. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepa-tocellular carcinoma. Hepatology 1995; 21: 313-321[PMID: 7843699 DOI: 10.1002/hep.1840210208]
18. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003; 60: 145-150[PMID: 14638411 DOI: 10.1016/ j.antiviral.2003.08.010]
19. Ishikawa T, Ichida T, Yamagiwa S, Sugahara S, Uehara K, Okoshi S, Asakura H. High viral loads, serum alanine ami-notransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274-1281[PMID: 11903747 DOI: 10.1046/j.1440-1746.2001.02616.x]
20. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-1673[PMID: 18616655 DOI: 10.1111/j.1572-0241.2008.01872.x]
21. Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, Qian C. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 1284-1291[PMID: 21913016 DOI: 10.1245/s10434-011-2042-3]
22. Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28: 393-401[PMID: 18028321 DOI: 10.1111/j.1478-3231.2007.01625.x]
23. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499PMID: 1656445 DOI: 10.1073/pnas.88.19.8495]
24. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tani-kawa K. Effcacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184[PMID: 16024289 DOI: 10.1016/j.hepres.2005.02.006]
25. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-1470[PMID: 20840396 DOI: 10.1111/j.1478-3231.2010.02344.x]
26. Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. The infuence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gas-troenterol 2009; 44: 991-999[PMID: 19554391 DOI: 10.1007/ s00535-009-0093-z]
27. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichika-wa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, Habu D, Nishiguchi S. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100[PMID: 17300703 DOI: 10.1111/j.1872-034X.2007.00013.x]
28. Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hi-rooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-1935[PMID: 17914972 DOI: 10.1111/j.1440-1746.2006.04707.x]
29. Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010; 17: 179-185[PMID: 19727956 DOI: 10.1245/s10434-009-0694-z]
30. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-224[PMID: 16286955]
31. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012; 308: 1906-1914[PMID: 23162861]
32. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013; 31: 3647-3655[PMID: 24002499 DOI: 10.1200/JCO.2012.48.5896]
33. Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Trans-arterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol 2012; 23: 317-22.e1[PMID: 22265248 DOI: 10.1016/ j.jvir.2011.11.012]
34. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, De-Hertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010[PMID: 16525137 DOI: 10.1056/NEJMoa051285]
35. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-1665[PMID: 17133475 DOI: 10.1002/hep.21422]
36. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high meta-static potential. Hepatology 2000; 32: 43-48[PMID: 10869287]
37. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fuka-hori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006; 26: 964-975[PMID: 16953837]
38. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastro-enterol 2006; 41: 1206-1213[PMID: 17287900 DOI: 10.1007/ s00535-006-1912-0]
39. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AW, Lin HJ. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 389-394[PMID: 8383088]
40. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842[PMID: 17522506]
41. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465[PMID: 16557381 DOI: 10.1007/s00432-006-0091-y]
42. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255: 8-17[PMID: 22104564 DOI: 10.1097/SLA.0b013e3182363ff9]
43. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.e3; quiz e13-4[PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007]
44. Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Mou-cari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7: 88-97[PMID: 23518903 DOI: 10.1007/s12072-012-9343-x]